chr2-47429740-A-C
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000251.3(MSH2):c.1077-2A>C variant causes a splice acceptor, intron change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★★).
Frequency
Consequence
NM_000251.3 splice_acceptor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Lynch syndrome 1 Pathogenic:2
This variant is considered pathogenic. This variant occurs within a consensus splice junction and is predicted to result in abnormal mRNA splicing of either an out-of-frame exon or an in-frame exon necessary for protein stability and/or normal function. This variant is strongly associated with more severe personal and family histories of cancer, typical for individuals with pathogenic variants in this gene [PMID: 27363726]. -
Multifactorial likelihood analysis posterior probability >0.99 -
Hereditary cancer-predisposing syndrome Pathogenic:2
This variant causes an A to C nucleotide substitution at the -2 position of intron 6 of the MSH2 gene. Splice site prediction tools suggest that this variant may have a significant impact on RNA splicing. Although this prediction has not been confirmed in published RNA studies, this variant is expected to result in an absent or disrupted protein product. This variant has been reported in individuals affected with Lynch syndrome (PMID: 14970868, 24278394). Microsatellite instability and loss of MSH2 protein expression have been demonstrated in tumor samples from these individuals. This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of MSH2 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. -
The c.1077-2A>C intronic pathogenic mutation results from an A to C substitution two nucleotides upstream from coding exon 7 in the MSH2 gene. This variant has been identified in probands who met Amsterdam I/II criteria for Lynch syndrome or had loss of MSH2 and MSH6 protein expression in their Lynch syndrome-associated tumors by immunohistochemistry (IHC) (Ambry internal data). Also, this variant was previously reported in one family fulfilling Amsterdam I criteria (De Lellis L, PLoS ONE 2013 ; 8(11):e81194) and in another family of Italian descent suspected of having HNPCC/Lynch syndrome (Ponz de Leon M, Br. J. Cancer 2004 Feb; 90(4):882-7). Tumor testing in both reported families showed loss of MSH2 protein expression by IHC and high microsatellite instability (MSI-H). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice acceptor site and will result in the creation or strengthening of a novel splice acceptor site. RNA studies have demonstrated this alteration results in abnormal splicing in the set of samples tested (Ambry internal data). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -
not specified Pathogenic:1
This variant is located in a canonical splice-acceptor site and interferes with normal MSH2 mRNA splicing. The variant has been reported in individuals with personal or family history of hereditary non-polyposis colorectal cancer (HNPCC) and urinary tract cancer in the published literature (PMID: 31615790 (2020), 24278394 (2013), 15849733 (2005), 14970868 (2004)). This variant has not been reported in large, multi-ethnic general populations (http://gnomad.broadinstitute.org). Based on the available information, this variant is classified as pathogenic. -
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
This sequence change affects an acceptor splice site in intron 6 of the MSH2 gene. RNA analysis indicates that disruption of this splice site induces altered splicing and may result in an absent or altered protein product. This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individuals with clinical features of Lynch syndrome (PMID: 24278394; internal data). This variant is also known as IVS6-2A>C. ClinVar contains an entry for this variant (Variation ID: 90528). Studies have shown that disruption of this splice site results in activation of a cryptic splice site, and produces a non-functional protein and/or introduces a premature termination codon (internal data). For these reasons, this variant has been classified as Pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at